The clinical relevance of these findings is underscored by the observation that 66.7% of patients with Cx43 gene mutations and aberrant protein localization presented with advanced tumor stages (IIIa or IIIb) compared to 37.5% in patients without mutations. Here, GJA1 is linked to neoplasm.